查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953499

單株抗體療法市場－全球產業規模、佔有率、趨勢、機會及預測（按產品類型、應用、生產來源、最終用戶、地區和競爭格局分類，2021-2031年）

Monoclonal Antibody Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By Production Source, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球單株抗體治療市場預計將從 2025 年的 2,472.1 億美元成長到 2031 年的 4,256.7 億美元，複合年成長率為 9.48%。

これらの治療薬は、標的細胞を攻撃する免疫システムの機能を回復,強化,模倣する代替抗体として機能するよう、実験室で設計された分子で構成されています。この市場成長は主に、がんや自體免疫疾患を含む慢性疾患の発生率上昇により、標的を絞った医療介入への強いニーズが生じていること、および高齢化が進む世界人口が老齡化に伴う疾患の効果的な管理を特定の生物学的治療を通じて求めていることが主な要因です。

市場概覽
預測期 2027-2031
市場規模：2025年 2472.1億美元
市場規模：2031年 4256.7億美元
複合年成長率：2026-2031年 9.48%
成長最快的細分市場 人性化
最大的市場 北美洲

然而，市場面臨與研發和生產相關的高成本等重大障礙，這可能限制患者的廣泛用藥，並加重醫療預算負擔。嚴格的監管標準進一步加劇了這些財務挑戰，延長了核准流程。為了凸顯產業為克服這些挑戰所做的持續努力，抗體協會報告稱，美國食品藥物管理局(FDA) 在 2024 年核准了15 種治療性抗體分子，這表明業界正持續努力應對監管方面的複雜問題，並將新的治療方法帶給患者。

市場促進因素

全球單株抗體療法市場的主要驅動力是個人化醫療和標靶治療的日益普及，而這又源自於對疾病發病機制更深入的臨床理解。醫療服務提供者越來越重視生物製藥製劑，領先的查核點抑制劑的成功，尤其是在腫瘤學和免疫學領域，便是最好的證明。默克在2024年2月發布的報告也印證了對高活性重磅藥物的依賴，該報告預測，Keytruda的全球年銷售額將在2023年成長19%，達到250億美元。

同時，旨在加速新一代抗體偶聯物（ADC）研發的策略性授權協議和合作正在重塑競爭格局。大型製藥公司正積極尋求收購，以避免漫長的藥物研發階段並確保寶貴的在研產品線。例如，輝瑞公司於2023年12月宣布，已完成對SeeGen的收購，企業價值約430億美元，使其腫瘤領域的資源加倍。這股勢頭在隔年得以延續。艾伯維公司在2024年2月的新聞稿中宣布，已完成對Immunogen的收購，總對價約101億美元，凸顯了對拓展ADC能力的重視。

市場挑戰

全球單株抗體療法市場的成長受到研發和生產這些複雜生物藥物所需巨額資本成本的顯著限制。與化學合成的小分子藥物不同，單株抗體依賴使用活細胞的複雜生產流程，需要嚴格的環境控制、昂貴的純化系統和嚴苛的品質保證。這種複雜性需要大量的資本投入，從而設置了很高的准入門檻，阻礙了小型生物技術公司的參與，並導致市場力量集中，最終限制了能夠降低價格的競爭多樣性。

高昂的營運成本導致最終治療產品價格居高不下，嚴重阻礙了市場滲透，限制了病患的用藥機會。醫療系統和私人支付者通常會設定嚴格的報銷標準以控制成本，導致許多合格的患者無法獲得所需的治療。根據歐洲製藥工業協會聯合會（EFPIA）預測，到2024年，歐洲以研發為基礎的製藥業預計將在研發方面投入550億歐元，凸顯了創新所需的巨額資金。這些財務壓力迫使製造商維持高價以收回投資，直接阻礙了對成本敏感的市場的產品普及率和銷售量成長。

市場趨勢

将人工智慧融入抗体工程和药物发现领域，正从根本上改变着药物研发模式，它能够从头设计出具有超越传统篩檢技术的优化特性的生物製藥。製藥公司正積極利用生成式人工智慧模型來預測蛋白質結構和結合親和性，進而縮短研發週期，並提高複雜多特異性抗體的成功率。這一趨勢在對Xaira Therapeutics等人工智慧原生生物技術公司的大規模投資中可見一斑。根據Fierce Biotech 2024年4月的一篇報導報道，該公司已籌集超過10億美元資金，並開始建立一個整合的、人工智慧驅動的藥物研發平台。

同時，市場正策略性地向神經退化性疾病領域擴張，挑戰免疫學和腫瘤學領域的傳統主導地位。近期，阿茲海默症疾病修正治療的核准，证明了单克隆抗体在清除BETA-淀粉样斑塊和延缓认知衰退方面的疗效，标志着该领域的一次决定性转变。這種潛力已開始在營收數據中顯現。百健公司在2024年10月公佈的數據顯示，其Rekembi第三季全球市場銷售額達到約6,700萬美元，顯示患者對此創新神經系統療法的接受度高，且相關基礎設施已相當完善。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球單株抗體治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（裸抗體、融合蛋白、抗體片段、偶聯物、多特異性抗體）
    • 用途別（がん、自體免疫疾患、感染疾病、その他）
    • 依生產來源（人類來源、人源化、嵌合體、其他）
    • エンドユーザー別（病院、専門医療センター、研究機関）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美單株抗體治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲單株抗體治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區單株抗體療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲單株抗體治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲單株抗體治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球單株抗體療法市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi SA
  • AstraZeneca inc.
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19082

The Global Monoclonal Antibody Therapeutics Market is projected to expand from USD 247.21 Billion in 2025 to USD 425.67 Billion by 2031, reflecting a compound annual growth rate of 9.48%. These therapeutics consist of molecules engineered in laboratories to function as substitute antibodies that can restore, enhance, or mimic the immune system's ability to attack target cells. This market growth is principally driven by the rising incidence of chronic diseases, including cancer and autoimmune disorders, which create a strong need for targeted medical interventions, alongside a growing global geriatric population that demands effective management of age-related illnesses through specific biologic treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 247.21 Billion
Market Size 2031USD 425.67 Billion
CAGR 2026-20319.48%
Fastest Growing SegmentHumanized
Largest MarketNorth America

However, the market encounters substantial obstacles related to the high costs inherent in development and manufacturing, which can restrict widespread patient access and impose strain on healthcare budgets. These financial hurdles are further complicated by stringent regulatory standards that extend the duration of the approval process. Highlighting the industry's continued dedication to overcoming these challenges, The Antibody Society reported that the US FDA approved 15 therapeutic antibody-based molecules in 2024, signaling sustained efforts to navigate regulatory complexities and bring new treatments to patients.

Market Driver

A primary catalyst for the global monoclonal antibody therapeutics market is the rising adoption of personalized medicine and targeted therapies, driven by a deeper clinical understanding of disease pathology. Healthcare providers are increasingly prioritizing biologics that deliver precise mechanisms against specific antigens, particularly within the fields of oncology and immunology, as evidenced by the success of leading checkpoint inhibitors. This reliance on high-efficacy blockbusters to meet critical unmet needs is illustrated by Merck & Co.'s report in February 2024, which noted that worldwide sales of Keytruda rose by 19 percent to reach $25.0 billion for the full year 2023.

Concurrently, the competitive landscape is being reshaped by strategic licensing agreements and collaborations aimed at accelerating the development of next-generation antibody-drug conjugates (ADCs). Major pharmaceutical companies are actively pursuing acquisitions to bypass lengthy discovery phases and secure valuable pipeline assets, a trend exemplified by Pfizer Inc.'s announcement in December 2023 that it completed the acquisition of Seagen for an enterprise value of approximately $43 billion to double its oncology resources. This momentum continued into the following year, as noted in a February 2024 press release from AbbVie Inc., which confirmed the finalization of its acquisition of ImmunoGen for a total equity value of roughly $10.1 billion, underscoring the intense focus on expanding ADC capabilities.

Market Challenge

The growth of the Global Monoclonal Antibody Therapeutics Market is heavily constrained by the immense financial costs involved in developing and manufacturing these complex biologic drugs. In contrast to chemically synthesized small molecules, monoclonal antibodies depend on intricate production methods using living cells, requiring strict environmental controls, costly purification systems, and rigorous quality assurance. This complexity necessitates significant capital expenditure, establishing high entry barriers that deter smaller biotechnology firms and consolidate market power, effectively limiting the competitive diversity required to foster price reductions.

These steep operational costs result in high prices for final therapeutic products, which severely limits market penetration and restricts patient access. Healthcare systems and private payers frequently impose stringent reimbursement criteria to control expenses, leaving many eligible patients without necessary treatments. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the research-based pharmaceutical industry invested an estimated €55,000 million in R&D in Europe in 2024, highlighting the substantial capital required for innovation; such financial pressure compels manufacturers to sustain high prices to recover investments, which directly impedes adoption rates and volume growth in cost-sensitive markets.

Market Trends

The integration of artificial intelligence into antibody engineering and discovery is fundamentally transforming the development model by allowing for the de novo design of biologics with optimized traits, surpassing traditional screening techniques. Pharmaceutical entities are increasingly utilizing generative AI models to forecast protein structures and binding affinities, thereby shortening development timelines and enhancing success rates for complex multispecific antibodies. This trend is highlighted by significant investment in AI-native biotech firms, such as Xaira Therapeutics, which, according to a Fierce Biotech article from April 2024, launched with over $1 billion in committed capital to establish an integrated AI-driven drug development platform.

In parallel, the market is undergoing a strategic expansion into neurodegenerative disorders, challenging the historical dominance of immunology and oncology indications. Recent regulatory approvals for disease-modifying Alzheimer's therapies have validated the effectiveness of monoclonal antibodies in removing amyloid-beta plaques and slowing cognitive decline, creating a pivotal shift in the sector. This potential is beginning to reflect in revenue data, as Biogen Inc. reported in October 2024 that global in-market sales of Leqembi reached approximately $67 million for the third quarter, indicating strong patient uptake and infrastructure readiness for these innovative neurologic treatments.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi S.A
  • AstraZeneca inc.
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc.

Report Scope

In this report, the Global Monoclonal Antibody Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Monoclonal Antibody Therapeutics Market, By Product Type

  • Naked
  • Fusion Protein
  • Antibody Fragment
  • Conjugate
  • Multi-specific

Monoclonal Antibody Therapeutics Market, By Application

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Others

Monoclonal Antibody Therapeutics Market, By Production Source

  • Human
  • Humanized
  • Chimeric
  • Others

Monoclonal Antibody Therapeutics Market, By End User

  • Hospital
  • Specialty Centers
  • Research Institutes

Monoclonal Antibody Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Monoclonal Antibody Therapeutics Market.

Available Customizations:

Global Monoclonal Antibody Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monoclonal Antibody Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Naked, Fusion Protein, Antibody Fragment, Conjugate, Multi-specific)
    • 5.2.2. By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Others)
    • 5.2.3. By Production Source (Human, Humanized, Chimeric, Others)
    • 5.2.4. By End User (Hospital, Specialty Centers, Research Institutes)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Monoclonal Antibody Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Production Source
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Monoclonal Antibody Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Production Source
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Monoclonal Antibody Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Production Source
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Monoclonal Antibody Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Production Source
        • 6.3.3.2.4. By End User

7. Europe Monoclonal Antibody Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Production Source
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Monoclonal Antibody Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Production Source
        • 7.3.1.2.4. By End User
    • 7.3.2. France Monoclonal Antibody Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Production Source
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Monoclonal Antibody Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Production Source
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Monoclonal Antibody Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Production Source
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Monoclonal Antibody Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Production Source
        • 7.3.5.2.4. By End User

8. Asia Pacific Monoclonal Antibody Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Production Source
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Monoclonal Antibody Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Production Source
        • 8.3.1.2.4. By End User
    • 8.3.2. India Monoclonal Antibody Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Production Source
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Monoclonal Antibody Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Production Source
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Monoclonal Antibody Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Production Source
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Monoclonal Antibody Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Production Source
        • 8.3.5.2.4. By End User

9. Middle East & Africa Monoclonal Antibody Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Production Source
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Monoclonal Antibody Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Production Source
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Monoclonal Antibody Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Production Source
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Monoclonal Antibody Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Production Source
        • 9.3.3.2.4. By End User

10. South America Monoclonal Antibody Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Production Source
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Monoclonal Antibody Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Production Source
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Monoclonal Antibody Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Production Source
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Monoclonal Antibody Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Production Source
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Monoclonal Antibody Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Merck & Co. Inc.
  • 15.4. Pfizer Inc.
  • 15.5. Eli Lilly and Co.
  • 15.6. Sanofi S.A
  • 15.7. AstraZeneca inc.
  • 15.8. Bayer AG
  • 15.9. Regeneron Pharmaceuticals Inc.
  • 15.10. GSK Plc.

16. Strategic Recommendations

17. About Us & Disclaimer